599 related articles for article (PubMed ID: 28720060)
21. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
22. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
23. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease.
Gong DH; Fan L; Chen HY; Ding KF; Yu KD
Oncotarget; 2016 May; 7(19):28570-8. PubMed ID: 27086913
[TBL] [Abstract][Full Text] [Related]
25. Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.
Woodman N; Pinder SE; Tajadura V; Le Bourhis X; Gillett C; Delannoy P; Burchell JM; Julien S
Int J Oncol; 2016 Jul; 49(1):265-75. PubMed ID: 27176937
[TBL] [Abstract][Full Text] [Related]
26. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
[TBL] [Abstract][Full Text] [Related]
27. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Hunt BG; Wicker CA; Bourn JR; Lower EE; Takiar V; Waltz SE
Breast Cancer Res Treat; 2020 Jun; 181(3):529-540. PubMed ID: 32342233
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis revealing prognostic significance of
Chen WX; Yang LG; Xu LY; Cheng L; Qian Q; Sun L; Zhu YL
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898978
[No Abstract] [Full Text] [Related]
29. Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
Hellwig B; Madjar K; Edlund K; Marchan R; Cadenas C; Heimes AS; Almstedt K; Lebrecht A; Sicking I; Battista MJ; Micke P; Schmidt M; Hengstler JG; Rahnenführer J
PLoS One; 2016; 11(12):e0167585. PubMed ID: 27926932
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
31. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.
Liu MT; Huang WT; Wang AY; Huang CC; Huang CY; Chang TH; Pi CP; Yang HH
Support Care Cancer; 2010 Dec; 18(12):1553-64. PubMed ID: 19904562
[TBL] [Abstract][Full Text] [Related]
32. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
33. Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.
Serrero G; Hawkins DM; Bejarano PA; Ioffe O; Tkaczuk KR; Elliott RE; Head JF; Phillips J; Godwin AK; Weaver J; Hicks D; Yue B
Diagn Pathol; 2016 Aug; 11(1):71. PubMed ID: 27501955
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in advanced breast cancer: Race and receptor status are significant after development of metastasis.
Ren Z; Li Y; Shen T; Hameed O; Siegal GP; Wei S
Pathol Res Pract; 2016 Jan; 212(1):24-30. PubMed ID: 26616114
[TBL] [Abstract][Full Text] [Related]
36. Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Tiirikainen M; Yu H
FEBS Open Bio; 2019 Jul; 9(7):1270-1280. PubMed ID: 31102318
[TBL] [Abstract][Full Text] [Related]
37. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.
Zhong X; Xie G; Zhang Z; Wang Z; Wang Y; Wang Y; Qiu Y; Li L; Bu H; Li J; Zheng H
Oncotarget; 2016 Sep; 7(38):61166-61182. PubMed ID: 27533459
[TBL] [Abstract][Full Text] [Related]
38. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
39. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
40. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Jiang YZ; Huang L; Zhou RJ; Yu KD; Liu Y; Shao ZM
Clin Cancer Res; 2013 Dec; 19(24):6853-62. PubMed ID: 24141623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
